These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 30349390)

  • 21. Incident type 2 diabetes and hip fracture risk: a population-based matched cohort study.
    Martinez-Laguna D; Tebe C; Javaid MK; Nogues X; Arden NK; Cooper C; Diez-Perez A; Prieto-Alhambra D
    Osteoporos Int; 2015 Feb; 26(2):827-33. PubMed ID: 25488807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis.
    Kim Y; Tian Y; Yang J; Huser V; Jin P; Lambert CG; Park H; You SC; Park RW; Rijnbeek PR; Van Zandt M; Reich C; Vashisht R; Wu Y; Duke J; Hripcsak G; Madigan D; Shah NH; Ryan PB; Schuemie MJ; Suchard MA
    Sci Rep; 2020 Jul; 10(1):11115. PubMed ID: 32632237
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis.
    Nicolopoulos K; Moshi MR; Stringer D; Ma N; Jenal M; Vreugdenburg T
    Arch Osteoporos; 2023 Jan; 18(1):18. PubMed ID: 36624318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative Fracture Risk During Osteoporosis Drug Holidays After Long-Term Risedronate Versus Alendronate Therapy : A Propensity Score-Matched Cohort Study.
    Hayes KN; Brown KA; Cheung AM; Kim SA; Juurlink DN; Cadarette SM
    Ann Intern Med; 2022 Mar; 175(3):335-343. PubMed ID: 35007149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low incidence of anti-osteoporosis treatment after hip fracture.
    Rabenda V; Vanoverloop J; Fabri V; Mertens R; Sumkay F; Vannecke C; Deswaef A; Verpooten GA; Reginster JY
    J Bone Joint Surg Am; 2008 Oct; 90(10):2142-8. PubMed ID: 18829912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of competing mortality risks on predictive performance of the QFracture risk prediction tool for major osteoporotic fracture and hip fracture: external validation cohort study in a UK primary care population.
    Livingstone SJ; Morales DR; McMinn M; Eke C; Donnan P; Guthrie B
    BMJ Med; 2022; 1(1):e000316. PubMed ID: 36936595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased fracture risk after discontinuation of anti-osteoporosis medications among hip fracture patients: A population-based cohort study.
    Fu SH; Wang CY; Hung CC; Lee CC; Yang RS; Huang CC; Farn CJ; Lin WH; Chen HM; Hsiao FY; Lin JW; Li CY
    J Intern Med; 2021 Dec; 290(6):1194-1205. PubMed ID: 34237171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis.
    Reginster JY
    Drugs; 2011 Jan; 71(1):65-78. PubMed ID: 21175240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Impact of Various Anti-Osteoporosis Drugs on All-Cause Mortality After Hip Fractures: A Nationwide Population Study.
    Tai TW; Hwang JS; Li CC; Hsu JC; Chang CW; Wu CH
    J Bone Miner Res; 2022 Aug; 37(8):1520-1526. PubMed ID: 35689432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of Alendronate and Risk of Cardiovascular Events in Patients With Hip Fracture.
    Sing CW; Wong AY; Kiel DP; Cheung EY; Lam JK; Cheung TT; Chan EW; Kung AW; Wong IC; Cheung CL
    J Bone Miner Res; 2018 Aug; 33(8):1422-1434. PubMed ID: 29744914
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.
    Albert SG; Reddy S
    Endocr Pract; 2017 Jul; 23(7):841-856. PubMed ID: 28448754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does Routine Anti-Osteoporosis Medication Lower the Risk of Fractures in Male Subjects? An Updated Systematic Review With Meta-Analysis of Clinical Trials.
    Zeng LF; Pan BQ; Liang GH; Luo MH; Cao Y; Guo D; Chen HY; Pan JK; Huang HT; Liu Q; Guan ZT; Han YH; Zhao D; Zhao JL; Hou SR; Wu M; Lin JT; Li JH; Liang WX; Ou AH; Wang Q; Yang WY; Liu J
    Front Pharmacol; 2019; 10():882. PubMed ID: 31447677
    [No Abstract]   [Full Text] [Related]  

  • 34. Evaluating the comparability of osteoporosis treatments using propensity score and negative control outcome methods in UK and Denmark electronic health record databases.
    Tan EH; Rathod-Mistry T; Strauss VY; O'Kelly J; Giorgianni F; Baxter R; Brunetti VC; Pedersen AB; Ehrenstein V; Prieto-Alhambra D
    J Bone Miner Res; 2024 Aug; 39(7):844-854. PubMed ID: 38619297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predicting Imminent Fractures in Patients With a Recent Fracture or Starting Oral Bisphosphonate Therapy: Development and International Validation of Prognostic Models.
    Khalid S; Pineda-Moncusí M; El-Hussein L; Delmestri A; Ernst M; Smith C; Libanati C; Toth E; Javaid MK; Cooper C; Abrahamsen B; Prieto-Alhambra D
    J Bone Miner Res; 2021 Nov; 36(11):2162-2176. PubMed ID: 34342378
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of strontium ranelate on bone mineral density in men with osteoporosis.
    Ringe JD; Dorst A; Farahmand P
    Arzneimittelforschung; 2010; 60(5):267-72. PubMed ID: 20533764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased Fracture Risk in Women Treated With Aromatase Inhibitors Versus Tamoxifen: Beneficial Effect of Bisphosphonates.
    Pineda-Moncusí M; Garcia-Giralt N; Diez-Perez A; Servitja S; Tusquets I; Prieto-Alhambra D; Nogués X
    J Bone Miner Res; 2020 Feb; 35(2):291-297. PubMed ID: 31596961
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®).
    Kanis JA; Johansson H; Oden A; McCloskey EV
    Osteoporos Int; 2011 Aug; 22(8):2347-55. PubMed ID: 21287148
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of antiresorptive medications in women on long-term dialysis after hip fracture: A population-based cohort study.
    Lin YC; Lee TC; Chen CY; Lin SJ; Hwang SJ; Lin MY
    PLoS One; 2020; 15(9):e0238248. PubMed ID: 32877436
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs--an analysis using national health databases.
    Olsen KR; Hansen C; Abrahamsen B
    Osteoporos Int; 2013 Oct; 24(10):2639-47. PubMed ID: 23604250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.